BioDelivery Sciences International, Inc.
) is expected to report second quarter 2014 results on Aug 8,
Last quarter, BioDelivery Sciences posted a 100.0% positive
surprise. However, on an average, BioDelivery Sciences has posted a
14.64% negative surprise in the last four quarters. Let's see how
things are shaping up for the second quarter.
Factors to Influence Q2 Results
Revenues for the first quarter came in at $20.7 million, easily
beating the Zacks Consensus Estimate of $6 million.
In Jun 2014, the FDA approved BioDelivery Sciences' Bunavail
(buprenorphine and naloxone buccal film) for the maintenance
therapy of opioid dependence. BioDelivery Sciences plans to launch
Bunavail towards the end of the third quarter of 2014. The company
is currently working on the execution of sales, marketing and other
commercialization and product supply chain activities in order to
support the anticipated launch of Bunavail. We note that
BioDelivery Sciences entered into an agreement with Quintiles (
) to provide a range of services to support the anticipated launch
including the establishment of a sales team. However, we expect
operating expenses to increase significantly owing to the
Our proven model does not conclusively show that BioDelivery
Sciences will beat earnings this quarter. That is because a stock
needs to have both a positive
and a Zacks Rank #1, #2 or #3 to be able to beat consensus
estimates. That is not the case here as you will see below.
: The ESP, which represents the difference between the Most
Accurate estimate and the Zacks Consensus Estimate, is 0.00%. This
is because both the Most Accurate Estimate and the Zacks Consensus
Estimate currently stand at a loss of 7 cents.
Zacks Rank #3 (Hold)
: BioDelivery Sciences' Zacks Rank #3 (Hold) when combined with a
0.00% ESP makes surprise prediction difficult.
We caution against stocks with Zacks Ranks #4 and #5 (Sell-rated
stocks) going into the earnings announcement, especially when the
company is seeing negative estimate revisions.
Stocks to Consider
Here are some companies you may want to consider as our model
shows that these have the right combination of elements:
Myriad Genetics Inc. (
) has an Earnings ESP of +4.35% and a Zacks Rank #1 (Strong Buy).
Myriad Genetics will be reporting fiscal fourth quarter 2014
earnings on Aug 12, 2014.
Curis, Inc. (
) has an Earnings ESP of +33.3% and a Zacks Rank #2 (Buy). Curis
will be reporting second quarter results on Aug 7, 2014.
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
QUINTILES TRANS (Q): Free Stock Analysis Report
MYRIAD GENETICS (MYGN): Free Stock Analysis
CURIS INC (CRIS): Free Stock Analysis Report
BIODELIVERY SCI (BDSI): Free Stock Analysis
To read this article on Zacks.com click here.